Crossmark

Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis

Crossref DOI link: https://doi.org/10.1007/s00384-024-04745-1

Published Online: 2024-10-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Yen-Cheng

Chang, Tsung-Kun

Su, Wei-Chih

Yeh, Yung-Sung

Chen, Po-Jung

Huang, Peng-Jen

Yang, Po-Hsiang

Tsai, Hsiang-Lin

Wang, Jaw-Yuan

Huang, Ching-Wen
License Information

Text and Data Mining valid from 2024-10-25

Version of Record valid from 2024-10-25
More Information

Article History

Accepted: 21 October 2024

First Online: 25 October 2024

Declarations

:

: The present study protocol was approved by the Institutional Ethics Committee of Kaohsiung Medical University Hospital (KMUHIRB-E(I)-20230267). Consent to participate is not applicable due to retrospective study design.

: On behalf of all co-authors, the corresponding author has obtained the consent for publication.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below